Mechanisms of transport of polymeric and lipidic nanoparticles across the intestinal barrier

Advanced Drug Delivery Reviews

Volumn 106, Issue , 2016, Pages 242-255

  Beloqui, Ana ^a   des Rieux, Anne ^a   Préat, Véronique ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Caco 2; Endocytosis; HT29 MTX; In vitro models; M cells; Nanoparticles; Transport mechanisms

Indexed keywords

MOLECULAR BIOLOGY; POLYMERS;

CACO-2; ENDOCYTOSIS; HT29-MTX; IN-VITRO MODELS; M CELLS; TRANSPORT MECHANISM;

NANOPARTICLES;

INSULIN; LIPID NANOPARTICLE; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; POLYMERIC NANOPARTICLE; SAQUINAVIR; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; LIPID; POLYMER;

CACO 2 CELL LINE; CHEMICAL COMPOSITION; DRUG ABSORPTION; DRUG DESIGN; DRUG PENETRATION; DRUG TRANSPORT; ENDOCYTOSIS; ENTERITIS; GASTROINTESTINAL MUCOSA; HT 29 CELL LINE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; INTESTINE ABSORPTION; INTESTINE CELL; INTESTINE EPITHELIUM; INTESTINE MUCOSA; MEMBRANE TRANSPORT; MOLECULAR INTERACTION; MUCUS SECRETION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PERMEABILITY BARRIER; PHAGOCYTOSIS; PHYSICAL CHEMISTRY; PINOCYTOSIS; PRIORITY JOURNAL; REVIEW; SURFACE CHARGE; SURFACE PROPERTY; ANIMAL; CACO-2 CELL LINE; CHEMISTRY; INTESTINE; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; CACO-2 CELLS; HUMANS; INTESTINES; LIPIDS; NANOPARTICLES; POLYMERS;

EID: 84975718105     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.04.014     Document Type: Review

References (164)

1. [1] Artursson, P., Palm, K., Luthman, K., Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 46 (2001), 27–43.
2. [2] Behrens, I., Stenberg, P., Artursson, P., Kissel, T., Transport of lipophilic drug molecules in a new mucus-secreting cell culture model based on HT29-MTX cells. Pharm. Res. 18 (2001), 1138–1145.
3. [3] Clark, M.A., Jepson, M.A., Hirst, B.H., Exploiting M cells for drug and vaccine delivery. Adv. Drug Deliv. Rev. 50 (2001), 81–106.
4. [4] Gamboa, J.M., Leong, K.W., In vitro and in vivo models for the study of oral delivery of nanoparticles. Adv. Drug Deliv. Rev. 65 (2013), 800–810.
5. [5] Hillaireau, H., Couvreur, P., Nanocarriers’ entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci. 66 (2009), 2873–2896.
6. [6] Duncan, R., Richardson, S.C., Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges. Mol. Pharm. 9 (2012), 2380–2402.
7. [7] Duncan, R., Gaspar, R., Nanomedicine(s) under the microscope. Mol. Pharm. 8 (2011), 2101–2141.
8. [8] Sahay, G., Alakhova, D.Y., Kabanov, A.V., Endocytosis of nanomedicines. J. Control. Release 145 (2010), 182–195.
9. [9] Yameen, B., Choi, W.I., Vilos, C., Swami, A., Shi, J., Farokhzad, O.C., Insight into nanoparticle cellular uptake and intracellular targeting. J. Control. Release 190 (2014), 485–499.
10. [10] Hofmann, D., Mailänder, V., Pharmacology of nanocarriers on the microscale: importance of uptake mechanisms and intracellular trafficking for efficient drug delivery. Nanomedicine (London) 8 (2013), 321–323.
11. [11] Roger, E., Lagarce, F., Garcion, E., Benoit, J.P., Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine (London) 5 (2010), 287–306.
12. [12] Blanco, E., Shen, H., Ferrari, M., Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33 (2015), 941–951.
13. [13] Mitragotri, S., Burke, P.A., Langer, R., Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discov. 13 (2014), 655–672.
14. [14] Tarantini, A., Lanceleur, R., Mourot, A., Lavault, M.T., Casterou, G., Jarry, G., Hogeveen, K., Fessard, V., Toxicity, genotoxicity and proinflammatory effects of amorphous nanosilica in the human intestinal Caco-2 cell line. Toxicol. in Vitro 29 (2015), 398–407.
15. [15] Wang, Q., Strab, R., Kardos, P., Ferguson, C., Li, J., Owen, A., Hidalgo, I.J., Application and limitation of inhibitors in drug–transporter interactions studies. Int. J. Pharm. 356 (2008), 12–18.
16. [16] Artursson, P., Borchardt, R.T., Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm. Res. 14 (1997), 1655–1658.
17. [17] Alqahtani, S., Mohamed, L.A., Kaddoumi, A., Experimental models for predicting drug absorption and metabolism. Expert Opin. Drug Metab. Toxicol. 9 (2013), 1241–1254.
18. [18] Sandberg, A.S., The use of caco-2 cells to estimate fe absorption in humans—a critical appraisal. Int. J. Vitam. Nutr. Res. 80 (2010), 307–313.
19. [19] Abramov, E., Cassiola, F., Schwob, O., Karsh-Bluman, A., Shapero, M., Ellis, J., Luyindula, D., Adini, I., D'Amato, R.J., Benny, O., Cellular mechanism of oral absorption of solidified polymer micelles. Nanomedicine 11 (2015), 1993–2002.
20. [20] Alai, M., Lin, W.J., Application of nanoparticles for oral delivery of acid-labile lansoprazole in the treatment of gastric ulcer: in vitro and in vivo evaluations. Int. J. Nanomedicine 10 (2015), 4029–4041.
21. [21] Gossmann, R., Langer, K., Mulac, D., New perspective in the formulation and characterization of didodecyldimethylammonium bromide (DMAB) stabilized poly(lactic-co-glycolic acid) (PLGA) nanoparticles. PLoS One, 10, 2015, e0127532.
22. [22] Ke, Z., Guo, H., Zhu, X., Jin, Y., Huang, Y., Efficient peroral delivery of insulin via vitamin B12 modified trimethyl chitosan nanoparticles. J. Pharm. Pharm. Sci. 18 (2015), 155–170.
23. [23] Ledet, G.A., Graves, R.A., Glotser, E.Y., Mandal, T.K., Bostanian, L.A., Preparation and in vitro evaluation of hydrophilic fenretinide nanoparticles. Int. J. Pharm. 479 (2015), 329–337.
24. [24] Tukulula, M., Hayeshi, R., Fonteh, P., Meyer, D., Ndamase, A., Madziva, M.T., Khumalo, V., Lubuschagne, P., Naicker, B., Swai, H., Dube, A., Curdlan-conjugated PLGA nanoparticles possess macrophage stimulant activity and drug delivery capabilities. Pharm. Res. 32 (2015), 2713–2726.
25. [25] Zhu, S., Chen, S., Gao, Y., Guo, F., Li, F., Xie, B., Zhou, J., Zhong, H., Enhanced oral bioavailability of insulin using PLGA nanoparticles co-modified with cell-penetrating peptides and Engrailed secretion peptide (Sec). Drug Deliv., 1-12, 2015.
26. [26] Duran-Lobato, M., Martin-Banderas, L., Lopes, R., Goncalves, L.M., Fernandez-Arevalo, M., Almeida, A.J., Lipid nanoparticles as an emerging platform for cannabinoid delivery: physicochemical optimization and biocompatibility. Drug Dev. Ind. Pharm., 1-9, 2015.
27. [27] Huang, J., Shu, Q., Wang, L., Wu, H., Wang, A.Y., Mao, H., Layer-by-layer assembled milk protein coated magnetic nanoparticle enabled oral drug delivery with high stability in stomach and enzyme-responsive release in small intestine. Biomaterials 39 (2015), 105–113.
28. [28] Mykhaylyk, O., Sanchez-Antequera, Y., Vlaskou, D., Cerda, M.B., Bokharaei, M., Hammerschmid, E., Anton, M., Plank, C., Magnetic nanoparticle and magnetic field assisted siRNA delivery in vitro. Methods Mol. Biol. 1218 (2015), 53–106.
29. [29] Wang, M., Sun, B., Feng, J., Zhang, H., Liu, B., Li, C., Chen, Y., Zhang, Y., Kong, W., Investigation of transport mechanism of exendin-4 across Madin Darby canine kidney cell monolayers. Biol. Pharm. Bull. 35 (2012), 745–752.
30. [30] Zakrzewski, S.S., Richter, J.F., Krug, S.M., Jebautzke, B., Lee, I.F., Rieger, J., Sachtleben, M., Bondzio, A., Schulzke, J.D., Fromm, M., Gunzel, D., Improved cell line IPEC-J2, characterized as a model for porcine jejunal epithelium. PLoS One, 8, 2013, e79643.
31. [31] Devreese, M., Pasmans, F., De Backer, P., Croubels, S., An in vitro model using the IPEC-J2 cell line for efficacy and drug interaction testing of mycotoxin detoxifying agents. Toxicol. in Vitro 27 (2013), 157–163.
32. [32] Beduneau, A., Tempesta, C., Fimbel, S., Pellequer, Y., Jannin, V., Demarne, F., Lamprecht, A., A tunable Caco-2/HT29-MTX co-culture model mimicking variable permeabilities of the human intestine obtained by an original seeding procedure. Eur. J. Pharm. Biopharm. 87 (2014), 290–298.
33. [33] Groo, A.C., Mircheva, K., Bejaud, J., Ailhas, C., Panaiotov, I., Saulnier, P., Ivanova, T., Lagarce, F., Development of 2D and 3D mucus models and their interactions with mucus-penetrating paclitaxel-loaded lipid nanocapsules. Pharm. Res. 31 (2014), 1753–1765.
34. [34] Li, N., Wang, D., Sui, Z., Qi, X., Ji, L., Wang, X., Yang, L., Development of an improved three-dimensional in vitro intestinal mucosa model for drug absorption evaluation. Tissue Eng. Part C Methods 19 (2013), 708–719.
35. [35] Pereira, C., Araújo, F., Barrias, C.C., Granja, P.L., Sarmento, B., Dissecting stromal-epithelial interactions in a 3D in vitro cellularized intestinal model for permeability studies. Biomaterials 56 (2015), 36–45.
36. [36] Neutra, M.R., Pringault, E., Kraehenbuhl, J.P., Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annu. Rev. Immunol. 14 (1996), 275–300.
37. [37] Rieux, A. des, Ragnarsson, E.G., Gullberg, E., Préat, V., Schneider, Y.J., Artursson, P., Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur. J. Pharm. Sci. 25 (2005), 455–465.
38. [38] Ragnarsson, E.G., Schoultz, I., Gullberg, E., Carlsson, A.H., Tafazoli, F., Lerm, M., Magnusson, K.E., Soderholm, J.D., Artursson, P., Yersinia pseudotuberculosis induces transcytosis of nanoparticles across human intestinal villus epithelium via invasin-dependent macropinocytosis. Lab. Investig. 88 (2008), 1215–1226.
39. [39] Kerneis, S., Bogdanova, A., Kraehenbuhl, J.P., Pringault, E., Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria. Science 277 (1997), 949–952.
40. [40] Gullberg, E., Leonard, M., Karlsson, J., Hopkins, A.M., Brayden, D., Baird, A.W., Artursson, P., Expression of specific markers and particle transport in a new human intestinal M-cell model. Biochem. Biophys. Res. Commun. 279 (2000), 808–813.
41. [41] Rieux, A. des, Fievez, V., Théate, I., Mast, J., Préat, V., Schneider, Y.J., An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Eur. J. Pharm. Sci. 30 (2007), 380–391.
42. [42] Bouwmeester, H., Poortman, J., Peters, R.J., Wijma, E., Kramer, E., Makama, S., Puspitaninganindita, K., Marvin, H.J., Peijnenburg, A.A., Hendriksen, P.J., Characterization of translocation of silver nanoparticles and effects on whole-genome gene expression using an in vitro intestinal epithelium coculture model. ACS Nano 5 (2011), 4091–4103.
43. [43] Araujo, F., Pereira, C., Costa, J., Barrias, C., Granja, P.L., Sarmento, B., In vitro M-like cells genesis through a tissue-engineered triple-culture intestinal model. J. Biomed. Mater. Res. B Appl. Biomater., 2015 (in press).
44. [44] Schimpel, C., Teubl, B., Absenger, M., Meindl, C., Fröhlich, E., Leitinger, G., Zimmer, A., Roblegg, E., Development of an advanced intestinal in vitro triple culture permeability model to study transport of nanoparticles. Mol. Pharm. 11 (2014), 808–818.
45. [45] Gonzalez-Hernandez, M.B., Liu, T., Blanco, L.P., Auble, H., Payne, H.C., Wobus, C.E., Murine norovirus transcytosis across an in vitro polarized murine intestinal epithelial monolayer is mediated by M-like cells. J. Virol. 87 (2013), 12685–12693.
46. [46] Nahidi, L., Day, A.S., Lemberg, D.A., Leach, S.T., Differential effects of nutritional and non-nutritional therapies on intestinal barrier function in an in vitro model. J. Gastroenterol. 47 (2012), 107–117.
47. [47] Ranaldi, G., Ferruzza, S., Canali, R., Leoni, G., Zalewski, P.D., Sambuy, Y., Perozzi, G., Murgia, C., Intracellular zinc is required for intestinal cell survival signals triggered by the inflammatory cytokine TNFalpha. J. Nutr. Biochem. 24 (2013), 967–976.
48. [48] Katz, O., Reifen, R., Lerner, A., beta-Carotene can reverse dysregulation of iron protein in an in vitro model of inflammation. Immunol. Res. 61 (2015), 70–78.
49. [49] Beguin, P., Errachid, A., Larondelle, Y., Schneider, Y.J., Effect of polyunsaturated fatty acids on tight junctions in a model of the human intestinal epithelium under normal and inflammatory conditions. Food Funct. 4 (2013), 923–931.
50. [50] Hollebeeck, S., Winand, J., Herent, M.F., During, A., Leclercq, J., Larondelle, Y., Schneider, Y.J., Anti-inflammatory effects of pomegranate (Punica granatum L.) husk ellagitannins in Caco-2 cells, an in vitro model of human intestine. Food Funct. 3 (2012), 875–885.
51. [51] Van De Walle, J., Hendrickx, A., Romier, B., Larondelle, Y., Schneider, Y.J., Inflammatory parameters in Caco-2 cells: effect of stimuli nature, concentration, combination and cell differentiation. Toxicol. in Vitro 24 (2010), 1441–1449.
52. [52] Sergent, T., Piront, N., Meurice, J., Toussaint, O., Schneider, Y.J., Anti-inflammatory effects of dietary phenolic compounds in an in vitro model of inflamed human intestinal epithelium. Chem. Biol. Interact. 188 (2010), 659–667.
53. [53] Wang, W., Xia, T., Yu, X., Wogonin suppresses inflammatory response and maintains intestinal barrier function via TLR4-MyD88-TAK1-mediated NF-kappaB pathway in vitro. Inflamm. Res. 64 (2015), 423–431.
54. [54] Smirnova, M.G., Guo, L., Birchall, J.P., Pearson, J.P., LPS up-regulates mucin and cytokine mRNA expression and stimulates mucin and cytokine secretion in goblet cells. Cell. Immunol. 221 (2003), 42–49.
55. [55] Vallette, G., Jarry, A., Lemarre, P., Branka, J.E., Laboisse, C.L., NO-dependent and NO-independent IL-1 production by a human colonic epithelial cell line under inflammatory stress. Br. J. Pharmacol. 121 (1997), 187–192.
56. [56] Frontela-Saseta, C., Lopez-Nicolas, R., Gonzalez-Bermudez, C.A., Martinez-Gracia, C., Ros-Berruezo, G., Anti-inflammatory properties of fruit juices enriched with pine bark extract in an in vitro model of inflamed human intestinal epithelium: the effect of gastrointestinal digestion. Food Chem. Toxicol. 53 (2013), 94–99.
57. [57] Vermeer, I.T., Henderson, L.Y., Moonen, E.J., Engels, L.G., Dallinga, J.W., van Maanen, J.M., Kleinjans, J.C., Neutrophil-mediated formation of carcinogenic N-nitroso compounds in an in vitro model for intestinal inflammation. Toxicol. Lett. 154 (2004), 175–182.
58. [58] Leonard, F., Collnot, E.M., Lehr, C.M., A three-dimensional coculture of enterocytes, monocytes and dendritic cells to model inflamed intestinal mucosa in vitro. Mol. Pharm. 7 (2010), 2103–2119.
59. [59] Susewind, J., de Souza Carvalho-Wodarz, C., Repnik, U., Collnot, E.M., Schneider-Daum, N., Griffiths, G.W., Lehr, C.M., A 3D co-culture of three human cell lines to model the inflamed intestinal mucosa for safety testing of nanomaterials. Nanotoxicology 10 (2015), 53–62.
60. [60] Ghadimi, D., Helwig, U., Schrezenmeir, J., Heller, K.J., de Vrese, M., Epigenetic imprinting by commensal probiotics inhibits the IL-23/IL-17 axis in an in vitro model of the intestinal mucosal immune system. J. Leukoc. Biol. 92 (2012), 895–911.
61. [61] Juuti-Uusitalo, K., Klunder, L.J., Sjollema, K.A., Mackovicova, K., Ohgaki, R., Hoekstra, D., Dekker, J., van Ijzendoorn, S.C., Differential effects of TNF (TNFSF2) and IFN-γ on intestinal epithelial cell morphogenesis and barrier function in three-dimensional culture. PLoS One, 6, 2011, e22967.
62. [62] Elamin, E., Jonkers, D., Juuti-Uusitalo, K., van Ijzendoorn, S., Troost, F., Duimel, H., Broers, J., Verheyen, F., Dekker, J., Masclee, A., Effects of ethanol and acetaldehyde on tight junction integrity: in vitro study in a three dimensional intestinal epithelial cell culture model. PLoS One, 7, 2012, e35008.
63. [63] Elamin, E., Masclee, A., Juuti-Uusitalo, K., van Ijzendoorn, S., Troost, F., Pieters, H.J., Dekker, J., Jonkers, D., Fatty acid ethyl esters induce intestinal epithelial barrier dysfunction via a reactive oxygen species-dependent mechanism in a three-dimensional cell culture model. PLoS One, 8, 2013, e58561.
64. [64] Ludidi, S., Jonkers, D., Elamin, E., Pieters, H.J., Schaepkens, E., Bours, P., Kruimel, J., Conchillo, J., Masclee, A., The intestinal barrier in irritable bowel syndrome: subtype-specific effects of the systemic compartment in an in vitro model. PLoS One, 10, 2015, e0123498.
65. [65] Jarry, A., Cremet, L., Caroff, N., Bou-Hanna, C., Mussini, J.M., Reynaud, A., Servin, A.L., Mosnier, J.F., Lievin-Le Moal, V., Laboisse, C.L., Subversion of human intestinal mucosa innate immunity by a Crohn's disease-associated E. coli. Mucosal Immunol. 8 (2015), 572–581.
66. [66] Butler, M., Ng, C.Y., van Heel, D.A., Lombardi, G., Lechler, R., Playford, R.J., Ghosh, S., Modulation of dendritic cell phenotype and function in an in vitro model of the intestinal epithelium. Eur. J. Immunol. 36 (2006), 864–874.
67. [67] Bermudez-Brito, M., Munoz-Quezada, S., Gomez-Llorente, C., Matencio, E., Romero, F., Gil, A., Lactobacillus paracasei CNCM I-4034 and its culture supernatant modulate Salmonella-induced inflammation in a novel transwell co-culture of human intestinal-like dendritic and Caco-2 cells. BMC Microbiol., 15, 2015, 79.
68. [68] Plapied, L., Duhem, N., Rieux, A. des, Préat, V., Fate of polymeric nanocarriers for oral drug delivery, Curr Opin Colloid. Interface Sci.` 16 (2011), 228–237.
69. [69] Conner, S.D., Schmid, S.L., Regulated portals of entry into the cell. Nature 422 (2003), 37–44.
70. [70] Ruiz de Garibay, A.P., Solinís Aspiazu, M., Rodríguez Gascón, A., Ganjian, H., Fuchs, R., Role of endocytic uptake in transfection efficiency of solid lipid nanoparticles-based nonviral vectors. J. Gene Med. 15 (2013), 427–440.
71. [71] Bareford, L.M., Swaan, P.W., Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev. 59 (2007), 748–758.
72. [72] Xu, Y., Xu, J., Shan, W., Liu, M., Cui, Y., Li, L., Liu, C., Huang, Y., The transport mechanism of integrin αvβ3 receptor targeting nanoparticles in Caco-2 cells. Int. J. Pharm. 500 (2016), 42–53.
73. [73] Ghaffarian, R., Muro, S., Models and methods to evaluate transport of drug delivery systems across cellular barriers. J. Vis. Exp., 2013, e50638.
74. [74] Mrsny, R.J., Lessons from nature: “Pathogen-Mimetic” systems for mucosal nano-medicines. Adv. Drug Deliv. Rev. 61 (2009), 172–192.
75. [75] Trapani, A., Lopedota, A., Franco, M., Cioffi, N., Ieva, E., Garcia-Fuentes, M., Alonso, M.J., A comparative study of chitosan and chitosan/cyclodextrin nanoparticles as potential carriers for the oral delivery of small peptides. Eur. J. Pharm. Biopharm. 75 (2010), 26–32.
76. [76] Sonaje, K., Chuang, E.Y., Lin, K.J., Yen, T.C., Su, F.Y., Tseng, M.T., Sung, H.W., Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: microscopic, ultrastructural, and computed-tomographic observations. Mol. Pharm. 9 (2012), 1271–1279.
77. [77] Dünnhaupt, S., Barthelmes, J., Köllner, S., Sakloetsakun, D., Shahnaz, G., Düregger, A., Bernkop-Schnürch, A., Thiolated nanocarriers for oral delivery of hydrophilic macromolecular drugs. Carbohydr. Polym. 117 (2015), 577–584.
78. [78] Yamaki, T., Kamiya, Y., Ohtake, K., Uchida, M., Seki, T., Ueda, H., Kobayashi, J., Morimoto, Y., Natsume, H., A mechanism enhancing macromolecule transport through paracellular spaces induced by poly-L-arginine: poly-L-arginine induces the internalization of tight junction proteins via clathrin-mediated endocytosis. Pharm. Res. 31 (2014), 2287–2296.
79. [79] Pridgen, E.M., Alexis, F., Kuo, T.T., Levy-Nissenbaum, E., Karnik, R., Blumberg, R.S., Langer, R., Farokhzad, O.C., Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery. Sci. Transl. Med., 5, 2013, 213ra167.
80. [80] Rieux, A. des, Pourcelle, V., Cani, P.D., Marchand-Brynaert, J., Préat, V., Targeted nanoparticles with novel non-peptidic ligands for oral delivery. Adv. Drug Deliv. Rev. 65 (2013), 833–844.
81. [81] Yun, Y., Cho, Y.W., Park, K., Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv. Drug Deliv. Rev. 65 (2013), 822–832.
82. [82] Mathot, F., Rieux, A. des, Ariën, A., Schneider, Y.J., Brewster, M., Préat, V., Transport mechanisms of mmePEG750P(CL-co-TMC) polymeric micelles across the intestinal barrier. J. Control. Release 124 (2007), 134–143.
83. [83] Beloqui, A., Solinís, M., Gascón, A.R., del Pozo-Rodríguez, A., Rieux, A. des, Préat, V., Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J. Control. Release 166 (2013), 115–123.
84. [84] Veiseh, O., Tang, B.C., Whitehead, K.A., Anderson, D.G., Langer, R., Managing diabetes with nanomedicine: challenges and opportunities. Nat. Rev. Drug Discov. 14 (2015), 45–57.
85. [85] Delgado, D., del Pozo-Rodríguez, A., Solinís, M.Á., Rodríguez-Gascón, A., Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection: the importance of the entry pathway. Eur. J. Pharm. Biopharm. 79 (2011), 495–502.
86. [86] He, B., Lin, P., Jia, Z., Du, W., Qu, W., Yuan, L., Dai, W., Zhang, H., Wang, X., Wang, J., Zhang, X., Zhang, Q., The transport mechanisms of polymer nanoparticles in Caco-2 epithelial cells. Biomaterials 34 (2013), 6082–6098.
87. [87] Roger, E., Lagarce, F., Garcion, E., Benoit, J.P., Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J. Control. Release 140 (2009), 174–181.
88. [88] Jin, Y., Song, Y., Zhu, X., Zhou, D., Chen, C., Zhang, Z., Huang, Y., Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials 33 (2012), 1573–1582.
89. [89] Song, Q., Yao, L., Huang, M., Hu, Q., Lu, Q., Wu, B., Qi, H., Rong, Z., Jiang, X., Gao, X., Chen, J., Chen, H., Mechanisms of transcellular transport of wheat germ agglutinin-functionalized polymeric nanoparticles in Caco-2 cells. Biomaterials 33 (2012), 6769–6782.
90. [90] Ma, Z., Lim, L.Y., Uptake of chitosan and associated insulin in Caco-2 cell monolayers: a comparison between chitosan molecules and chitosan nanoparticles. Pharm. Res. 20 (2003), 1812–1819.
91. [91] Song, Q., Wang, X., Hu, Q., Huang, M., Yao, L., Qi, H., Qiu, Y., Jiang, X., Chen, J., Chen, H., Gao, X., Cellular internalization pathway and transcellular transport of pegylated polyester nanoparticles in Caco-2 cells. Int. J. Pharm. 445 (2013), 58–68.
92. [92] Fievez, V., Plapied, L., Plaideau, C., Legendre, D., Rieux, A. des, Pourcelle, V., Freichels, H., Jérôme, C., Marchand, J., Préat, V., Schneider, Y.J., In vitro identification of targeting ligands of human M cells by phage display. Int. J. Pharm. 394 (2010), 35–42.
93. [93] Mao, S., Germershaus, O., Fischer, D., Linn, T., Schnepf, R., Kissel, T., Uptake and transport of PEG-graft-trimethyl-chitosan copolymer-insulin nanocomplexes by epithelial cells. Pharm. Res. 22 (2005), 2058–2068.
94. [94] Roger, E., Lagarce, F., Garcion, E., Benoit, J.P., Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells. Eur. J. Pharm. Sci. 40 (2010), 422–429.
95. [95] Cartiera, M.S., Johnson, K.M., Rajendran, V., Caplan, M.J., Saltzman, W.M., The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials 30 (2009), 2790–2798.
96. [96] Reix, N., Parat, A., Seyfritz, E., Van der Werf, R., Epure, V., Ebel, N., Danicher, L., Marchioni, E., Jeandidier, N., Pinget, M., Frère, Y., Sigrist, S., In vitro uptake evaluation in Caco-2 cells and in vivo results in diabetic rats of insulin-loaded PLGA nanoparticles. Int. J. Pharm. 437 (2012), 213–220.
97. [97] Li, G., Lin, D.-H., Xie, X.-X., Qin, L.-F., Wang, J.-T., Liu, K., Uptake and transport of furanodiene in Caco-2 cell monolayers: a comparison study between furanodiene and furanodiene loaded PLGA nanoparticles. Chin. J. Nat. Med. 11 (2013), 49–55.
98. [98] Sheng, J., Han, L., Qin, J., Ru, G., Li, R., Wu, L., Cui, D., Yang, P., He, Y., Wang, J., N-trimethyl chitosan chloride-coated PLGA nanoparticles overcoming multiple barriers to oral insulin absorption. ACS Appl. Mater. Interfaces 7 (2015), 15430–15441.
99. [99] Weissenboeck, A., Bogner, E., Wirth, M., Gabor, F., Binding and uptake of wheat germ agglutinin-grafted PLGA-nanospheres by caco-2 monolayers. Pharm. Res. 21 (2004), 1917–1923.
100. [100] Siew, A., Le, H., Thiovolet, M., Gellert, P., Schatzlein, A., Uchegbu, I., Enhanced oral absorption of hydrophobic and hydrophilic drugs using quaternary ammonium palmitoyl glycol chitosan nanoparticles. Mol. Pharm. 9 (2012), 14–28.
101. [101] Sadeghi, A.M., Dorkoosh, F.A., Avadi, M.R., Weinhold, M., Bayat, A., Delie, F., Gurny, R., Larijani, B., Rafiee-Tehrani, M., Junginger, H.E., Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells. Eur. J. Pharm. Biopharm. 70 (2008), 270–278.
102. [102] Yin, L., Ding, J., He, C., Cui, L., Tang, C., Yin, C., Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials 30 (2009), 5691–5700.
103. [103] Han, L., Zhao, Y., Yin, L., Li, R., Liang, Y., Huang, H., Pan, S., Wu, C., Feng, M., Insulin-loaded pH-sensitive hyaluronic acid nanoparticles enhance transcellular delivery. AAPS PharmSciTech 13 (2012), 836–845.
104. [104] Sezgin, Z., Yuksel, N., Baykara, T., Investigation of pluronic and PEG-PE micelles as carriers of meso-tetraphenyl porphine for oral administration. Int. J. Pharm. 332 (2007), 161–167.
105. [105] Kitchens, K.M., Foraker, A.B., Kolhatkar, R.B., Swaan, P.W., Ghandehari, H., Endocytosis and interaction of poly (amidoamine) dendrimers with Caco-2 cells. Pharm. Res. 24 (2007), 2138–2145.
106. [106] Kitchens, K.M., Kolhatkar, R.B., Swaan, P.W., Ghandehari, H., Endocytosis inhibitors prevent poly(amidoamine) dendrimer internalization and permeability across Caco-2 cells. Mol. Pharm. 5 (2008), 364–369.
107. [107] Kitchens, K.M., El-Sayed, M.E., Ghandehari, H., Transepithelial and endothelial transport of poly (amidoamine) dendrimers. Adv. Drug Deliv. Rev. 57 (2005), 2163–2176.
108. [108] Alonso-Sande, M., Rieux, A. des, Fievez, V., Sarmento, B., Delgado, A., Evora, C., Remuñán-López, C., Préat, V., Alonso, M.J., Development of PLGA-mannosamine nanoparticles as oral protein carriers. Biomacromolecules 14 (2013), 4046–4052.
109. [109] Rieux, A. des, Fievez, V., Momtaz, M., Detrembleur, C., Alonso-Sande, M., Van Gelder, J., Cauvin, A., Schneider, Y.J., Préat, V., Helodermin-loaded nanoparticles: characterization and transport across an in vitro model of the follicle-associated epithelium. J. Control. Release 118 (2007), 294–302.
110. [110] Fievez, V., Plapied, L., Rieux, A. des, Pourcelle, V., Freichels, H., Wascotte, V., Vanderhaeghen, M.L., Jerôme, C., Vanderplasschen, A., Marchand-Brynaert, J., Schneider, Y.J., Préat, V., Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination. Eur. J. Pharm. Biopharm. 73 (2009), 16–24.
111. [111] Garinot, M., Fiévez, V., Pourcelle, V., Stoffelbach, F., Rieux, A. des, Plapied, L., Theate, I., Freichels, H., Jérôme, C., Marchand-Brynaert, J., Schneider, Y.J., Préat, V., PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J. Control. Release 120 (2007), 195–204.
112. [112] Plapied, L., Vandermeulen, G., Vroman, B., Préat, V., Rieux, A. des, Bioadhesive nanoparticles of fungal chitosan for oral DNA delivery. Int. J. Pharm. 398 (2010), 210–218.
113. [113] Kadiyala, I., Loo, Y., Roy, K., Rice, J., Leong, K.W., Transport of chitosan-DNA nanoparticles in human intestinal M-cell model versus normal intestinal enterocytes. Eur. J. Pharm. Sci. 39 (2010), 103–109.
114. [114] Wen, Z., Li, G., Lin, D., Wang, J., Qin, L., Guo, G., Transport of PLGA nanoparticles across Caco-2/HT29-MTX co-cultured cells. Yao Xue Xue Bao 48 (2013), 1829–1835.
115. [115] Behrens, I., Pena, A.I., Alonso, M.J., Kissel, T., Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm. Res. 19 (2002), 1185–1193.
116. [116] Zhang, J., Zhu, X., Jin, Y., Shan, W., Huang, Y., Mechanism study of cellular uptake and tight junction opening mediated by goblet cell-specific trimethyl chitosan nanoparticles. Mol. Pharm. 11 (2014), 1520–1532.
117. [117] Araújo, F., Shrestha, N., Shahbazi, M.A., Liu, D., Herranz-Blanco, B., Mäkilä, E.M., Salonen, J.J., Hirvonen, J.T., Granja, P.L., Sarmento, B., Santos, H.A., Microfluidic assembly of a multifunctional tailorable composite system designed for site specific combined oral delivery of peptide drugs. ACS Nano 9 (2015), 8291–8302.
118. [118] Coco, R., Plapied, L., Pourcelle, V., Jérôme, C., Brayden, D.J., Schneider, Y.J., Préat, V., Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. Int. J. Pharm. 440 (2013), 3–12.
119. [119] Leonard, F., Ali, H., Collnot, E.M., Crielaard, B.J., Lammers, T., Storm, G., Lehr, C.M., Screening of budesonide nanoformulations for treatment of inflammatory bowel disease in an inflamed 3D cell-culture model. ALTEX 29 (2012), 275–285.
120. [120] Danhier, F., Ansorena, E., Silva, J.M., Coco, R., Le Breton, A., Préat, V., PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release 161 (2012), 505–522.
121. [121] Gaumet, M., Gurny, R., Delie, F., Localization and quantification of biodegradable particles in an intestinal cell model: the influence of particle size. Eur. J. Pharm. Sci. 36 (2009), 465–473.
122. [122] Desai, M.P., Labhasetwar, V., Walter, E., Levy, R.J., Amidon, G.L., The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res. 14 (1997), 1568–1573.
123. [123] Panyam, J., Zhou, W.Z., Prabha, S., Sahoo, S.K., Labhasetwar, V., Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 16 (2002), 1217–1226.
124. [124] Rieux, A. des, Fievez, V., Garinot, M., Schneider, Y.J., Préat, V., Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 116 (2006), 1–27.
125. [125] Thanou, M., Verhoef, J.C., Junginger, H.E., Oral drug absorption enhancement by chitosan and its derivatives. Adv. Drug Deliv. Rev. 52 (2001), 117–126.
126. [126] Mourya, V.K., Inamdar, N.N., Trimethyl chitosan and its applications in drug delivery. J. Mater. Sci. Mater. Med. 20 (2009), 1057–1079.
127. [127] Araújo, F., Shrestha, N., Shahbazi, M.A., Fonte, P., Mäkilä, E.M., Salonen, J.J., Hirvonen, J.T., Granja, P.L., Santos, H.A., Sarmento, B., The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium. Biomaterials 35 (2014), 9199–9207.
128. [128] Lehr, C.M., Gabor, F., Lectins and glycoconjugates in drug delivery and targeting. Adv. Drug Deliv. Rev. 56 (2004), 419–420.
129. [129] Chen, M.C., Mi, F.L., Liao, Z.X., Hsiao, C.W., Sonaje, K., Chung, M.F., Hsu, L.W., Sung, H.W., Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules. Adv. Drug Deliv. Rev. 65 (2013), 865–879.
130. [130] Sandri, G., Bonferoni, M.C., Rossi, S., Ferrari, F., Gibin, S., Zambito, Y., Di Colo, G., Caramella, C., Nanoparticles based on N-trimethylchitosan: evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models. Eur. J. Pharm. Biopharm. 65 (2007), 68–77.
131. [131] Slutter, B., Plapied, L., Fievez, V., Sande, M.A., Rieux, A. des, Schneider, Y.J., Van Riet, E., Jiskoot, W., Préat, V., Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J. Control. Release 138 (2009), 113–121.
132. [132] Lopes, M.A., Abrahim, B.A., Cabral, L.M., Rodrigues, C.R., Seiça, R.M., de Baptista Veiga, F.J., Ribeiro, A.J., Intestinal absorption of insulin nanoparticles: contribution of M cells. Nanomedicine 10 (2014), 1139–1151.
133. [133] Gaucher, G., Satturwar, P., Jones, M.C., Furtos, A., Leroux, J.C., Polymeric micelles for oral drug delivery. Eur. J. Pharm. Biopharm. 76 (2010), 147–158.
134. [134] Joshi, G., Kumar, A., Sawant, K., Enhanced bioavailability and intestinal uptake of Gemcitabine HCl loaded PLGA nanoparticles after oral delivery. Eur. J. Pharm. Sci. 60 (2014), 80–89.
135. [135] Wang, X.Q., Zhang, Q., pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs. Eur. J. Pharm. Biopharm. 82 (2012), 219–229.
136. [136] Beloqui, A., Coco, R., Memvanga, P.B., Ucakar, B., Rieux, A. des, Préat, V., pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. Int. J. Pharm. 473 (2014), 203–212.
137. [137] Lu, Y., Park, K., Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int. J. Pharm. 453 (2013), 198–214.
138. [138] El-Sayed, M., Ginski, M., Rhodes, C., Ghandehari, H., Transepithelial transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers. J. Control. Release 81 (2002), 355–365.
139. [139] D'Emanuele, A., Jevprasesphant, R., Penny, J., Attwood, D., The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J. Control. Release 95 (2004), 447–453.
140. [140] Batrakova, E.V., Li, S., Vinogradov, S.V., Alakhov, V.Y., Miller, D.W., Kabanov, A.V., Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J. Pharmacol. Exp. Ther. 299 (2001), 483–493.
141. [141] Batrakova, E.V., Li, S., Li, Y., Alakhov, V.Y., Kabanov, A.V., Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm. Res. 21 (2004), 2226–2233.
142. [142] Zastre, J., Jackson, J.K., Wong, W., Burt, H.M., Methoxypolyethylene glycol-block-polycaprolactone diblock copolymers reduce P-glycoprotein efflux in the absence of a membrane fluidization effect while stimulating P-glycoprotein ATPase activity. J. Pharm. Sci. 96 (2007), 864–875.
143. [143] Elamanchili, P., McEachern, C., Burt, H., Reversal of multidrug resistance by methoxypolyethylene glycol-block-polycaprolactone diblock copolymers through the inhibition of P-glycoprotein function. J. Pharm. Sci. 98 (2009), 945–958.
144. [144] Zhang, X., Qi, J., Lu, Y., He, W., Li, X., Wu, W., Biotinylated liposomes as potential carriers for the oral delivery of insulin. Nanomedicine 10 (2014), 167–176.
145. [145] Shah, M.K., Madan, P., Lin, S., Elucidation of intestinal absorption mechanism of carvedilol-loaded solid lipid nanoparticles using Caco-2 cell line as an in-vitro model. Pharm. Dev. Technol., 1-9, 2014.
146. [146] Lasa-Saracíbar, B., Guada, M., Sebastián, V., Blanco-Prieto, M.J., In vitro intestinal co-culture cell model to evaluate intestinal absorption of edelfosine lipid nanoparticles. Curr. Top. Med. Chem. 14 (2014), 1124–1132.
147. [147] Luo, Y., Teng, Z., Li, Y., Wang, Q., Solid lipid nanoparticles for oral drug delivery: chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake. Carbohydr. Polym. 122 (2015), 221–229.
148. [148] Liu, Y., Wang, P., Sun, C., Feng, N., Zhou, W., Yang, Y., Tan, R., Chen, Z., Wu, S., Zhao, J., Wheat germ agglutinin-grafted lipid nanoparticles: preparation and in vitro evaluation of the association with Caco-2 monolayers. Int. J. Pharm. 397 (2010), 155–163.
149. [149] Memvanga, P.B., Coco, R., Préat, V., An oral malaria therapy: curcumin-loaded lipid-based drug delivery systems combined with β-arteether. J. Control. Release 172 (2013), 904–913.
150. [150] Fonte, P., Nogueira, T., Gehm, C., Ferreira, D., Sarmento, B., Chitosan-coated solid lipid nanoparticles enhance the oral absorption of insulin. Drug Deliv. Transl. Res. 1 (2011), 299–308.
151. [151] Fan, T., Chen, C., Guo, H., Xu, J., Zhang, J., Zhu, X., Yang, Y., Zhou, Z., Li, L., Huang, Y., Design and evaluation of solid lipid nanoparticles modified with peptide ligand for oral delivery of protein drugs. Eur. J. Pharm. Biopharm. 88 (2014), 518–528.
152. [152] Beloqui, A., Solinís, M.Á., Rieux, A. des, Préat, V., Rodríguez-Gascón, A., Dextran–protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs. Int. J. Pharm. 468 (2014), 105–111.
153. [153] Shi, L.L., Cao, Y., Zhu, X.Y., Cui, J.H., Cao, Q.R., Optimization of process variables of zanamivir-loaded solid lipid nanoparticles and the prediction of their cellular transport in Caco-2 cell model. Int. J. Pharm. 478 (2014), 60–69.
154. [154] Yucel, C., Degim, Z., Yilmaz, S., Nanoparticle and liposome formulations of doxycycline: transport properties through Caco-2 cell line and effects on matrix metalloproteinase secretion. Biomed. Pharmacother. 67 (2013), 459–467.
155. [155] Almeida, A.J., Souto, E., Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 59 (2007), 478–490.
156. [156] Beloqui, A., Solinís, M., Rodríguez-Gascón, A., Almeida, A.J., Préat, V., Nanostructured Lipid Carriers: promising drug delivery systems for future clinics. Nanomedicine 12 (2016), 143–161.
157. [157] Du, X., Zhang, J., Zhang, Y., Li, S., Lin, X., Tang, X., Wang, Y., Decanoic acid grafted oligochitosan nanoparticles as a carrier for insulin transport in the gastrointestinal tract. Carbohydr. Polym. 111 (2014), 433–441.
158. [158] Chen, C., Xhu, X., Dou, Y., Xu, J., Zhang, J., Fan, T., Du, J., Liu, K., Deng, Y., Zhao, L., Huang, Y., Exendin-4 loaded nanoparticles with a liquid shell and aqueous core containing micells for enhanced intestinal absorption. J. Biomed. Nanotechnol. 11 (2015), 865–876.
159. [159] Estella-Hermoso de Mendoza, A., Préat, V., Mollinedo, F., Blanco-Prieto, M.J., In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J. Control. Release 156 (2011), 421–426.
160. [160] Di, L., Artursson, P., Avdeef, A., Ecker, G.F., Faller, B., Fischer, H., Houston, J.B., Kansy, M., Kerns, E.H., Krämer, S.D., Lennernäs, H., Sugano, K., Evidence-based approach to assess passive diffusion and carrier-mediated drug transport. Drug Discov. Today 17 (2012), 905–912.
161. [161] Iversen, T.-G., Skotland, T., Sandvig, K., Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies. Nano Today 6 (2011), 176–185.
162. [162] Fitzgerald, K.A., Malhotra, M., Curtin, C.M., O'Brien, F.J., O'Driscoll, C.M., Life in 3D is never flat: 3D models to optimise drug delivery. J. Control. Release 215 (2015), 39–54.
163. [163] Braakhuis, H.M., Kloet, S.K., Kezic, S., Kuper, F., Park, M.V., Bellmann, S., van der Zande, M., Le Gac, S., Krystek, P., Peters, R.J., Rietjens, I.M., Bouwmeester, H., Progress and future of in vitro models to study translocation of nanoparticles. Arch. Toxicol. 89 (2015), 1469–1495.
164. [164] Lefebvre, D.E., Venema, K., Gombau, L., Valerio, L.G., Raju, J., Bondy, G.S., Bouwmeester, H., Singh, R.P., Clippinger, A.J., Collnot, E.M., Mehta, R., Stone, V., Utility of models of the gastrointestinal tract for assessment of the digestion and absorption of engineered nanomaterials released from food matrices. Nanotoxicology 9 (2015), 523–542.